In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating

Journal of Antimicrobial Chemotherapy

Volumn 42, Issue 6, 1998, Pages 779-785

  Petit, Caroline ^a   Chéron, Monique ^a   Joly, Véronique ^b   Rodrigues, José Maciel ^c,d   Bolard, Jacques ^a   Gaboriau, François ^a  

^a CNRS   (France)

^b BICHAT HOSPITAL   (France)

^c UNIV PARIS SUD   (France)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE;

ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CRYPTOCOCCUS; DRUG ACTIVITY; DRUG TOXICITY; HEATING; INTRAVENOUS DRUG ADMINISTRATION; LD 50; MENINGOENCEPHALITIS; MOUSE; MYCOSIS; NONHUMAN; SURVIVAL TIME;

EID: 0032428829     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/42.6.779     Document Type: Article

References (29)

1. Hartsel, S. & Bolard, J. (1996). Amphotericin B: new life for an old drug. Trends in Pharmacological Sciences 17, 445-9.
2. Ribaud, P. (1997). Fungal infections and the cancer patient. European Journal of Cancer 33, Suppl. 4, 50-4.
3. Legrand, P., Romero, E. A., Cohen, B. E. & Bolard, J. (1992). Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Antimicrobial Agents and Chemotherapy 36, 2518-22.
4. Bolard, J., Joly, V. & Yeni, P. (1993). Mechanism of action of amphotericin B at the cellular level. Its modulation by delivery system. Journal of Liposome Research 3, 409-27.
5. Wasan, K. M. & Lopez-Berestein, G. (1997). Diversity of lipid-based polyene formulations and their behavior in biological systems. European Journal of Clinical and Microbiological Infectious Diseases 16, 81-92.
6. Vertut-Doï, A., Ohnishi, S.-I. & Bolard, J. (1994). The endocytic process in CHO cells, a toxic pathway of the polyene antibiotic amphotericin B. Antimicrobial Agents and Chemotherapy 38, 2373-9.
7. Brajtburg, J. & Bolard, J. (1996). Carrier effects on biological activity of amphotericin B. Clininical Microbiology Reviews 9, 512-31.
8. Hillery, A. M. (1997). Supramolecular lipidic drug delivery systems: from laboratory to clinic. A review of recently introduced commercial liposomal and lipid-based formulations of amphotericin B. Advanced Drug Delivery Reviews 24, 345-63.
9. Gaboriau, F., Cheron, M., Leroy, L. & Bolard, J. (1997). Physicochemical properties of the heat-induced 'superaggregates' of amphotericin B. Biophysical Chemistry 66, 1-12.
10. Gaboriau, F., Cheron, M., Petit, C. & Bolard, J. (1997). Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index. Antimicrobial Agents and Chemotherapy 41, 2345-51.
11. Brajtburg, J., Elberg, S., Travis, S. J. & Kobayashi, G. S. (1994). Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles. Antimicrobial Agents and Chemotherapy 38, 294-9.
12. Dromer, F., Perronne, C., Barge, J., Vilde, J. L. & Yeni, P. (1989). Role of IgG and complement component C5 in the initial course of experimental cryptococcosis. Clinical and Experimental Immunology 78, 412-7.
13. Joly, V., Farinotti, R., Saint-Julien, L., Cheron, M., Carbon, C. & Yeni, P. (1994). In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid. Antimicrobial Agents and Chemotherapy 38, 177-83.
14. Saint-Julien, L., Joly, V., Seman, M., Carbon, C. & Yeni, P. (1992). Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycoses. Antimicrobial Agents and Chemotherapy 36, 2722-8.
15. Barchiesi, F., Colombo, A. L., McGough, D. A. & Rinaldi, M. G. (1994). Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard. Journal of Clinical Microbiology 32, 2494-500.
16. Galgiani, J. (1993). Susceptibility testing of fungi: current status of the standardization process. Antimicrobial Agents and Chemotherapy 37, 2517-21.
17. Litchfield, J. T. & Wilcoxon, F. (1949). Simplified method of evaluating dose-effect experiments. Journal of Pharmacology and Experimental Therapeutics 96, 99-113.
18. Ahmad, I., Sarkar, A. K. & Bachhawat, B. K. (1990). Effect of cholesterol in various liposomal compositions of the in vivo toxicity, therapeutic efficacy and tissue distribution of amphotericin B. Biotechnology and Applied Biochemistry 12, 550-6.
19. Tabosa do Egito, E. S., Appel, M., Fessi, H., Barratt, G., Puisieux, F. & Devissaguet, J. P. (1995). In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system. Journal of Antimicrobial Chemotherapy 38, 485-97.
20. Legrand, P., Cheron, M., Leroy, L. & Bolard, J. (1997). Release of amphotericin B from delivery systems and its action against fungal and mammalian cells. Journal of Drug Targeting 4, 311-9.
21. Wasan, K. M., Grossie, V. B. & Lopez-Berestein, G. (1994). Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion. Antimicrobial Agents and Chemotherapy 38, 2224-6.
22. Wasan, K. M., Rosenblum, M. G., Cheung, L. & Lopez-Berestein, G. (1994). Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B. Antimicrobial Agents and Chemotherapy 38, 223-7.
23. de Marie, S., Janknegt, R. & Bakker-Woudenberg, I. A. (1994). Clinical use of liposomal and lipid-complexed amphotericin B. Journal of Antimicrobial Chemotherapy 33, 907-16.
24. Adler-Moore, J. P., Chiang, S.-M., Satorius, A., Guerra, D., McAndrews, B., McManus, E. J. et al. (1991). Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). Journal of Antimicrobial Chemotherapy 28, Suppl. B, 63-71.
25. Adler-Moore, J. P. & Proffitt, R. T. (1993). Development, characterisation, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. Journal of Liposome Research 3, 429-50.
26. Coker, R. J., Murphy, S. M. & Harris, J. R. W. (1991). Experience with liposomal amphotericin B (AmBisome) in cryptococcal meningitis in AIDS. Journal of Antimicrobial Chemotherapy 28, Suppl. B, 105-9.
27. Chopra, R., Blair, S., Strang, J., Cervi, P., Patterson, K. G. & Goldstone, A. H. (1991). Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. Journal of Antimicrobial Chemotherapy 28, Suppl. B, 93-104.
28. Proffitt, R. T., Satorius, A., Chiang, S.-M., Sullivan, L. & Adler-Moore, J. P. (1991). Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. Journal of Antimicrobial Chemotherapy 28, Suppl. B, 49-61.
29. Wasan, K. M. & Conklin, J. S. (1996). Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidiasis. Antimicrobial Agents and Chemotherapy 40, 1806-10.